专题:Pharmacology and Obesity Treatment

This cluster of papers focuses on the pharmacological management of obesity, including the use of anti-obesity drugs, clinical trials evaluating their efficacy and safety, and the impact on weight loss. It covers a wide range of medications such as sibutramine, orlistat, and ephedra alkaloids, as well as their associated adverse events and lipase inhibitors.
最新文献
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes

article Full Text OpenAlex

Effectiveness of glucagon-like peptide-1 receptor agonists for reduction of body mass index and blood glucose control in patients with type 2 diabetes mellitus and obesity: A retrospective cohort study and difference-in-difference analysis

article Full Text OpenAlex

Semaglutide Versus Other Glucagon-Like Peptide-1 Agonists for Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis

review Full Text OpenAlex

Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials

review Full Text OpenAlex

Targeted Nano-Based Systems for the Anti-Obesity Agent’s Delivery

review Full Text OpenAlex

β-Cyclodextrin and APTES functionalized magnetic iron oxide nanoparticles for improved lipase immobilization, transesterification efficiency, and reusability

article Full Text OpenAlex

Prevalence of gastrointestinal manifestations among diabetic patients in the Aseer region: A cross-sectional study

article Full Text OpenAlex

Use of calculated free testosterone in men: advantages and limitations

review Full Text OpenAlex

Exploring flavonoid derivatives as potential pancreatic lipase inhibitors for obesity management: An in silico and in vitro study

article Full Text OpenAlex

Studying the Influence of Salt Concentrations on Betalain and Selected Physical and Chemical Properties in the Lactic Acid Fermentation Process of Red Beetroot

article Full Text OpenAlex

近5年高被引文献
Once-Weekly Semaglutide in Adults with Overweight or Obesity

article Full Text OpenAlex 3567 FWCI446.71051198

Tirzepatide Once Weekly for the Treatment of Obesity

article Full Text OpenAlex 2451 FWCI498.85349081

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

article Full Text OpenAlex 1848 FWCI620.61884303

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes

article Full Text OpenAlex 1087 FWCI365.30735151

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

article Full Text OpenAlex 1075 FWCI134.68562103

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes

article Full Text OpenAlex 1014 FWCI875.03391296

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity

article Full Text OpenAlex 992 FWCI113.72533883

KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease

article Full Text OpenAlex 977 FWCI205.36116446

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

article Full Text OpenAlex 846 FWCI118.93066964

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity

article Full Text OpenAlex 842 FWCI99.55288019